VTV’s diabetes reinvention gains some ground
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
Splitting the difference on promising pipeline asset predictions
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
EASL 2019 – Novo buys into Gilead’s Nash combo plan
Today’s deal will see the companies take a triple combination into clinical trials.
Upcoming events – Novo takes aim at type 1 diabetes and Aslan wants to roar
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Ascendis shoots higher on pivotal win
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
The sellside’s mid-term forecast: sunny with few hints of rain
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.